Antibody Drug Conjugates in Glioblastoma – Is There a Future for Them?
Glioblastoma (GBM) is an aggressive and fatal malignancy that despite decades of trials has limited therapeutic options. Antibody drug conjugates (ADCs) are composed of a monoclonal antibody which specifically recognizes a cellular surface antigen linked to a cytotoxic payload. ADCs have demonstrate...
Enregistré dans:
Auteurs principaux: | , , , |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Frontiers Media S.A.
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/75bd5259ae494948a7493d5c5e2d644f |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|